Will GoodRX Stock Bounce Back?
GoodRX (NASDAQ:GDRX) tracks prescription drug prices and its model was…
Sell
29
AZTA Quote, Financials, Valuation and Earnings
Last price:
$32.23
Seasonality move
:
-3.75%
Day range:
$31.43 - $32.46
52-week range:
$23.91 - $63.58
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
2.43x
P/B ratio:
0.86x
Volume:
598.3K
Avg. volume:
899.7K
1-year change:
-43.91%
Market cap:
$1.5B
Revenue:
$656.3M
EPS (TTM):
-$1.40
Analysts' Opinion
-
Consensus RatingAzenta has received a consensus rating of Hold. The company's average rating is a Hold based on 0 Buy ratings, 5 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $33.75, Azenta has an estimated upside of 5.21% from its current price of $32.08.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $30.00 representing 100% downside risk from its current price of $32.08.
Fair Value
-
According to the consensus of 5 analysts, Azenta has 5.21% upside to fair value with a price target of $33.75 per share.
AZTA vs. S&P 500
-
Over the past 5 trading days, Azenta has underperformed the S&P 500 by -3.93% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Azenta does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Azenta has grown year-over-year revenues for 2 quarters straight. In the most recent quarter Azenta reported revenues of $143.4M.
Earnings Growth
-
Azenta has grown year-over-year earnings for 2 quarters straight. In the most recent quarter Azenta reported earnings per share of -$0.88.
Enterprise value:
1.1B
EV / Invested capital:
--
Price / LTM sales:
2.43x
EV / EBIT:
--
EV / Revenue:
1.80x
PEG ratio (5yr expected):
-0.01x
EV / Free cash flow:
29.16x
Price / Operating cash flow:
39.43x
Enterprise value / EBITDA:
36.33x
Gross Profit (TTM):
$273M
Return On Assets:
-2.95%
Net Income Margin (TTM):
-10.31%
Return On Equity:
-3.48%
Return On Invested Capital:
-3.48%
Operating Margin:
-8.77%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $597.1M | $616.4M | $633.8M | $136.4M | $143.4M | |
| Gross Profit | $244.8M | $258.4M | $273M | $60.7M | $65.9M | |
| Operating Income | -$74.1M | -$63.8M | -$47.2M | -$16.1M | -$12.6M | |
| EBITDA | -$3.6M | $23.8M | $31.4M | $6.2M | $1.4M | |
| Diluted EPS | -$0.63 | -$2.71 | -$1.40 | -$2.47 | -$0.88 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $724.5M | $3B | $1.6B | $1.2B | $710.6M | |
| Total Assets | $1.7B | $4.2B | $3.2B | $2.6B | $2B | |
| Current Liabilities | $265.6M | $618M | $212.6M | $203M | $220.7M | |
| Total Liabilities | $398.1M | $694.1M | $354.6M | $340.6M | $340.4M | |
| Total Equity | $1.3B | $3.5B | $2.9B | $2.2B | $1.7B | |
| Total Debt | $50.1M | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$449.5M | $68.7M | $72.1M | $8.6M | $13.6M | |
| Cash From Investing | -$228.1M | $143.8M | $336.2M | -$272M | -$137.8M | |
| Cash From Financing | -$504.4M | -$520.9M | -$483.9M | -$72.4M | -$5.2M | |
| Free Cash Flow | -$500.3M | $31.4M | $39.1M | $364K | $7M | |
AZTA
Sector
Market Cap
$1.5B
$34.4M
Price % of 52-Week High
50.46%
48.88%
Dividend Yield
0%
0%
Shareholder Yield
29.75%
-1.01%
1-Year Price Total Return
-43.91%
-37.36%
Beta (5-Year)
1.637
0.614
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$32.77
200-day SMA
Sell
Level
$39.64
Bollinger Bands (100)
Buy
Level
26.11 - 37.53
Chaikin Money Flow
Buy
Level
51.8M
20-day SMA
Buy
Level
$31.54
Relative Strength Index (RSI14)
Buy
Level
54.45
ADX Line
Buy
Level
31.74
Williams %R
Neutral
Level
-55.6202
50-day SMA
Buy
Level
$29.38
MACD (12, 26)
Buy
Level
0.93
25-day Aroon Oscillator
Buy
Level
48
On Balance Volume
Neutral
Level
80M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (5.5418)
Buy
CA Score
(Annual)
Level (1.1732)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (2)
Buy
Ohlson Score
Level (-2.0061)
Buy
Piotroski F Score
(Annual)
Level (5)
Sell
Quality Ratio Score
Level (3)
Buy
Fundamental Score
Level (7)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Azenta Inc is a provider of life sciences solutions, enabling impactful breakthroughs and therapies to market faster. It provides a full suite of reliable cold-chain sample management solutions and genomic services across areas such as drug development, clinical research and cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. The company has three reportable segments that are Sample Management Solutions, Multiomics, and B Medical Systems. It generates a substantial part of its revenue from its Sample Management Solutions segment.
Stock Forecast FAQ
In the current month, AZTA has received 0 Buy ratings 5 Hold ratings, and 0 Sell ratings. The AZTA average analyst price target in the past 3 months is $33.75.
-
Where Will Azenta Stock Be In 1 Year?
According to analysts, the consensus estimate is that Azenta share price will rise to $33.75 per share over the next 12 months.
-
What Do Analysts Say About Azenta?
Analysts are divided on their view about Azenta share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Azenta is a Sell and believe this share price will drop from its current level to $30.00.
-
What Is Azenta's Price Target?
The price target for Azenta over the next 1-year time period is forecast to be $33.75 according to 5 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 5 analysts rate the stock a Hold.
-
Is AZTA A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Azenta is a Hold. 5 of 5 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of AZTA?
You can purchase shares of Azenta via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Azenta shares.
-
What Is The Azenta Share Price Today?
Azenta was last trading at $32.23 per share. This represents the most recent stock quote for Azenta. Yesterday, Azenta closed at $32.08 per share.
-
How To Buy Azenta Stock Online?
In order to purchase Azenta stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will FCX Benefit From Tariffs?
Freeport-McMoRan (NYSE:FCX) is among the world’s largest producers of copper…
Can Levi Stock Double?
Levi Strauss (NYSE:LEVI) is among the oldest clothing brands in…
Stock Ideas
Buy
70
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 58x
Buy
62
Is MSFT Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 43x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 35x
Alerts
Buy
82
SBET alert for Jul 17
SharpLink Gaming [SBET] is down 0.83% over the past day.
Buy
89
EXOD alert for Jul 17
Exodus Movement [EXOD] is down 5.71% over the past day.
Buy
60
U alert for Jul 17
Unity Software [U] is up 8.54% over the past day.
